1e
19
1
49
2
2
18
1b
1d
18
34
89
1d
2 29
1d
25
Kelley Weinfurtner, MD
88
89
Assistant Professor of Medicine (Gastroenterology) at the Hospital of the University of Pennsylvania
7
5f
Department: Medicine
4
1
b
1d
46
Contact information
67
4
3
3
3
2
4
b
1f
67
421 Curie Blvd, 910 BRB II/III
Philadelphia, PA 19104
26
Philadelphia, PA 19104
35
f
13
Education:
21 7 BA 39 (Bachelor of Arts, Molecular and Cell Biology) c
3a University of California Berkeley, 2007.
21 7 MD 1f (Doctor of Medicine) c
3f University of California San Francisco, 2015.
21 9 MSTR 23 (Translational Research) c
33 University of Pennsylvania, 2024.
c
3
3
3
3
8d
Permanent link21 7 BA 39 (Bachelor of Arts, Molecular and Cell Biology) c
3a University of California Berkeley, 2007.
21 7 MD 1f (Doctor of Medicine) c
3f University of California San Francisco, 2015.
21 9 MSTR 23 (Translational Research) c
33 University of Pennsylvania, 2024.
c
2 29
21
1e
1d
24
5e
71
e 29
27
Description of Clinical Expertise
e9 I am a transplant hepatologist who cares for patients with a wide range of liver problems. In particular, I have significant expertise in caring for patients with advanced liver disease and patients with liver tumors.71
Description of Research Expertise
104 My research is centered around developing precision medicine strategies for patients with primary liver cancers. In particular, I have expertise in developing patient-derived models of primary liver cancer for use in translational therapeutics.e 29
23
fd Weinfurtner K, Amin R, Skuli N, Gade TPF, Kaplan DE: Patient-derived models of liver cancer to inform therapeutic decision: recent updates. Seminars in Liver Disease February 2026.
10d Kim Y, McClung G, Wright C, Tischfield D, Furth EE, Kaffe E, Weinfurtner K, Gade TPF: Hepatocyte Humanization in an SRG Rat Model After Partial Hepatectomy. AASLD The Liver Meeting November 2025.
184 Hoteit MA, Abt PL, Priore SF, Tondon R, Abu-Gazala A, Agarwal P, Weinfurtner K, Hilscher MB, Wangensteeen KJ: Molecular patterns associated with recurrence and survival in intrahepatic cholangiocarcinoma (iCCA) / hepatocholangiocarcinoma (HCC-CCA) after liver transplantation. AASLD The Liver Meeting November 2025.
17f Ferrante ND, Hubbard RA, Weinfurtner K, Mezina AI, Newcomb CW, Furth EE, Bhattacharya D, Njei B, Taddei, TH, Singal A, Hoteit MA, Park LS, Kaplan DE, Lo Re V.: Validity of Diagnostic Codes and Laboratory Tests to Identify Cholangiocarcinoma and Its Subtypes. Pharmacoepidemiol Drug Saf 34(5): e70154, May 2025.
12f Hoteit M, Weinfurtner K: Recurrent hepatocellular carcinoma after liver transplantation: Small steps, while awaiting a breakthrough. Liver Transplantation April 2025 Notes: Online ahead of print. doi: 10.1097/LVT.0000000000000571.
194 Weinfurtner K, Tischfield D, McClung G, Crainic J, Gordan J, Jiao J, Furth EE, Li W, Tuzneen Supan E, Nadolski GJ, Hunt SJ, Kaplan DE, Gade TPF: Human GM-CSF/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts. JHep Reports 7(3): 101264, March 2025 Notes: https://doi.org/10.1016/j.jhepr.2024.101264.
120 Willis E, Verrelle J, Secreto A, Cole S, McClung G, Weinfurtner K, Gade TP, Radaelli E: Diagnostic Challenge in Veterinary Pathology: Otitis Media in a Humanized NOG-EXL Mouse. Vet Pathol 62(2): 113-116, March 2025.
158 Huang L, Dang QA, Wright, C, Gade TPF, Weinfurtner, K: Comparison of treatment response to chemoembolization and radioembolization in patients with intermediate stage hepatocellular carcinoma. Society of Interventional Oncology Annual Meeting February 2025 Notes: POSTER.
191 Habibollahi P, Gurevich A, Hui JZ, Weinfurtner K, McClung G, Adler J, Soulen MC, Kaplan DE, Nadolski GJ, Hunt SJ, Tsourkas A, and Gade TP: Integrated imaging probe and bispecific antibody development enables in vivo targeting of glypican-3-expressiong hepatocellular carcinoma. Mol Cancer Ther 23(12): 1815-1826, December 2024.
2c
7
1d
1f
Selected Publications
152 Yan L, Huang L, Wright C, Gade TPF, Weinfurtner K: Intra-patient tumor-level outcomes of transarterial chemoembolization versus transarterial radioembolization for multifocal hepatocellular carcinoma. Society of Interventional Oncology Annual Meeting February 2026.fd Weinfurtner K, Amin R, Skuli N, Gade TPF, Kaplan DE: Patient-derived models of liver cancer to inform therapeutic decision: recent updates. Seminars in Liver Disease February 2026.
10d Kim Y, McClung G, Wright C, Tischfield D, Furth EE, Kaffe E, Weinfurtner K, Gade TPF: Hepatocyte Humanization in an SRG Rat Model After Partial Hepatectomy. AASLD The Liver Meeting November 2025.
184 Hoteit MA, Abt PL, Priore SF, Tondon R, Abu-Gazala A, Agarwal P, Weinfurtner K, Hilscher MB, Wangensteeen KJ: Molecular patterns associated with recurrence and survival in intrahepatic cholangiocarcinoma (iCCA) / hepatocholangiocarcinoma (HCC-CCA) after liver transplantation. AASLD The Liver Meeting November 2025.
17f Ferrante ND, Hubbard RA, Weinfurtner K, Mezina AI, Newcomb CW, Furth EE, Bhattacharya D, Njei B, Taddei, TH, Singal A, Hoteit MA, Park LS, Kaplan DE, Lo Re V.: Validity of Diagnostic Codes and Laboratory Tests to Identify Cholangiocarcinoma and Its Subtypes. Pharmacoepidemiol Drug Saf 34(5): e70154, May 2025.
12f Hoteit M, Weinfurtner K: Recurrent hepatocellular carcinoma after liver transplantation: Small steps, while awaiting a breakthrough. Liver Transplantation April 2025 Notes: Online ahead of print. doi: 10.1097/LVT.0000000000000571.
194 Weinfurtner K, Tischfield D, McClung G, Crainic J, Gordan J, Jiao J, Furth EE, Li W, Tuzneen Supan E, Nadolski GJ, Hunt SJ, Kaplan DE, Gade TPF: Human GM-CSF/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts. JHep Reports 7(3): 101264, March 2025 Notes: https://doi.org/10.1016/j.jhepr.2024.101264.
120 Willis E, Verrelle J, Secreto A, Cole S, McClung G, Weinfurtner K, Gade TP, Radaelli E: Diagnostic Challenge in Veterinary Pathology: Otitis Media in a Humanized NOG-EXL Mouse. Vet Pathol 62(2): 113-116, March 2025.
158 Huang L, Dang QA, Wright, C, Gade TPF, Weinfurtner, K: Comparison of treatment response to chemoembolization and radioembolization in patients with intermediate stage hepatocellular carcinoma. Society of Interventional Oncology Annual Meeting February 2025 Notes: POSTER.
191 Habibollahi P, Gurevich A, Hui JZ, Weinfurtner K, McClung G, Adler J, Soulen MC, Kaplan DE, Nadolski GJ, Hunt SJ, Tsourkas A, and Gade TP: Integrated imaging probe and bispecific antibody development enables in vivo targeting of glypican-3-expressiong hepatocellular carcinoma. Mol Cancer Ther 23(12): 1815-1826, December 2024.
2c